Trial Profile
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mirvetuximab soravtansine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 02 Jul 2018 Planned End Date changed from 1 Dec 2020 to 28 Feb 2018.
- 02 Jul 2018 Planned primary completion date changed from 1 Mar 2019 to 28 Feb 2018.
- 02 Jul 2018 Status changed from recruiting to withdrawn prior to enrolment.